GS
Goldman Sachs Alternatives
New York, New York, United StatesFounded 1986
Biotech & Life SciencesCybersecurityTravel & HospitalityData & AnalyticsEducationConsumerSaaSLogistics & Supply Chain
Goldman Sachs Alternatives focuses on a broad spectrum of alternative investments, including private equity (buyout, growth equity, co-investments, and secondaries), private credit, real estate, infrastructure, sustainability, and hedge funds. Their strategy involves both direct investments and partnerships with third-party asset managers to deliver diversified solutions and long-term growth for clients.
Average disclosed round size is $359.1M (across 25 rounds with reported amounts).
Portfolio
29
Fund Size
—
Top Stage
Series C
Last 12 Mo
14
Team
JR
Josh Richardson
Principal
AL
Alexander Lippert
Gründer Und Geschäftsführer
CW
Colin Walsh
Managing Director
HP
Harris Pollack
Vice President
CL
Cedric Lucas
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
29 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Schellman | Unknown | — | Mar 2026 |
 Databricks | Growth | $5B | Feb 2026 |
 LearnWell | Unknown | — | Feb 2026 |
| LearnWell | Unknown | — | Feb 2026 |
 Fieldguide | Series C | $75M | Feb 2026 |
 Redwood Materials | Series E | $425M | Jan 2026 |
| CCubby | Series A | $63M | Jan 2026 |
 osapiens | Series C | $100M | Jan 2026 |
 Neural Concept | Series C | $100M | Dec 2025 |
 Peek | Series D | $70M | Nov 2025 |
 Skims | Growth | $225M | Nov 2025 |
 MoEngage | Series F | $100M | Nov 2025 |
 Simetrik | Series B | $30M | Jun 2025 |
 Bestow | Series D | $120M | May 2025 |
 Attovia Therapeutics | Series C | $90M | Apr 2025 |
 Fleetio | Series D | $450M | Mar 2025 |
 Mews | Series C | $75M | Mar 2025 |
 Tines | Series C | $125M | Feb 2025 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
 Vicebio | Series B | $100M | Sep 2024 |
| Vicebio | Series B | — | Sep 2024 |
| osapiens | Series B | $110.7M | Jul 2024 |
 Vanta | Series C | $150M | Jul 2024 |
 AlphaSense | Growth | $650M | Jun 2024 |
| Attovia Therapeutics | Series B | $105M | May 2024 |
Page 1 of 2
Top Co-Investors
Cormorant Asset Management3 shared
venBio3 shared
Viking Global Investors2 shared
J.P. Morgan2 shared
SoftBank Vision Fund2 shared
Deep Track Capital2 shared
Marshall Wace2 shared
Medicxi2 shared
Sequoia Capital2 shared
Goldman Sachs2 shared
Kinnevik2 shared
Alkeon Capital Management1 shared
Sanofi Ventures1 shared
World Innovation Lab1 shared
Mizuho Bank1 shared
Springcoast Partners1 shared
WestCap1 shared
A91 Partners1 shared
SignalFire1 shared
Vision Plus Capital1 shared
Last updated: 4 May 2026